Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 517-524

  Younis, Islam R ^a   Malone, Samuel ^b   Friedman, Henry S ^b   Schaaf, Larry J ^c   Petros, William P ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Enterohepatic recirculation; Irinotecan; Pharmacokinetics

Indexed keywords

7 ETHYL 10 [4 N ((5 AMINOPENTANOIC ACID) 1 PIPERIDINO) 1 AMINO] CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; IRINOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG BLOOD LEVEL; ENTEROHEPATIC CIRCULATION; FEMALE; GLIOMA; HUMAN; MALE; MATHEMATICAL MODEL; METABOLITE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REBOUND; RECURRENT CANCER; AREA UNDER THE CURVE; BRAIN TUMOR; HALF LIFE TIME; METABOLISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BRAIN NEOPLASMS; CAMPTOTHECIN; ENTEROHEPATIC CIRCULATION; FEMALE; GLIOMA; HALF-LIFE; HUMANS; MALE;

EID: 58249124985     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0769-8     Document Type: Article

References (30)

1. AR Clamp J Maenpaa D Cruickshank J Ledermann PM Wilkinson R Welch S Chan P Vasey B Sorbe A Hindley GC Jayson 2006 SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer Br J Cancer 94 1 55 61 (Pubitemid 43088541)
2. K Matsumoto N Katsumata Y Yamanaka K Yonemori T Kohno C Shimizu M Andoh Y Fujiwara 2006 The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer Gynecol Oncol 100 2 412 416 (Pubitemid 43075278)
3. HC Pitot DB Wender MJ O'Connell G Schroeder RM Goldberg J Rubin JA Mailliard JA Knost C Ghosh RJ Kirschling R Levitt HE Windschitl 1997 Phase II trial of irinotecan in patients with metastatic colorectal carcinoma J Clin Oncol 15 8 2910 2919 (Pubitemid 27330019)
4. JA Conti NE Kemeny LB Saltz Y Huang WP Tong TC Chou M Sun S Pulliam C Gonzalez 1996 Irinotecan is an active agent in untreated patients with metastatic colorectal cancer J Clin Oncol 14 3 709 715 (Pubitemid 26085513)
5. R Stupp ME Hegi MJ van den Bent WP Mason M Weller RO Mirimanoff JG Cairncross 2006 Changing paradigms-an update on the multidisciplinary management of malignant glioma Oncologist 11 2 165 180 (Pubitemid 43261763)
6. JG Slatter P Su JP Sams LJ Schaaf LC Wienkers 1997 Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metab Dispos 25 10 1157 1164 (Pubitemid 27446586)
7. R Humerickhouse K Lohrbach L Li WF Bosron ME Dolan 2000 Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res 60 5 1189 1192 (Pubitemid 30151980)
8. L Iyer CD King PF Whitington MD Green SK Roy TR Tephly BL Coffman MJ Ratain 1998 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 4 847 854 (Pubitemid 28096082)
9. LP Rivory J Robert 1995 Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan Cancer Chemother Pharmacol 36 2 176 179
10. G Catimel GG Chabot JP Guastalla A Dumortier C Cote C Engel A Gouyette A Mathieu-Boue M Mahjoubi M Clavel 1995 Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors Ann Oncol 6 2 133 140 (Pubitemid 41611625)
11. P Canal C Gay A Dezeuze JY Douillard R Bugat R Brunet A Adenis P Herait F Lokiec A Mathieu-Boue 1996 Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer J Clin Oncol 14 10 2688 2695 (Pubitemid 26329653)
12. A Santos S Zanetta T Cresteil A Deroussent F Pein E Raymond L Vernillet ML Risse V Boige A Gouyette G Vassal 2000 Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin Cancer Res 6 5 2012 2020 (Pubitemid 30305100)
13. GG Chabot 1997 Clinical pharmacokinetics of irinotecan Clin Pharmacokinet 33 4 245 259 (Pubitemid 27429892)
14. HS Friedman WP Petros AH Friedman LJ Schaaf T Kerby J Lawyer M Parry PJ Houghton S Lovell K Rasheed T Cloughsey ES Stewart OM Colvin JM Provenzale RE [tmp] McLendon DD Bigner I Cokgor M Haglund J Rich D Ashley J Malczyn GL Elfring LL Miller 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 5 1516 1525 (Pubitemid 29220860)
15. GG Chabot D Abigerges G Catimel S Culine M de Forni JM Extra M Mahjoubi P Herait JP Armand R Bugat M Clave ME Marty 1995 Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials Ann Oncol 6 2 141 151
16. D'Argenio Schumitzky (1997) ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
17. K Yamaoka T Nakagawa T Uno 1978 Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations J Pharmacokinet Biopharm 6 2 165 175 (Pubitemid 8384279)
18. RG Azrak J Yu L Pendyala PF Smith S Cao X Li WD Shannon FA Durrani HL [tmp] McLeod YM Rustum 2005 Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors Mol Cancer Ther 4 5 843 854 (Pubitemid 40767129)
19. MD Prados WK Yung KA Jaeckle HI Robins MP Mehta HA Fine PY Wen TF Cloughesy SM Chang MK Nicholas D Schiff HS Greenberg L Junck KL Fink KR Hess J Kuhn 2004 Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro Oncol 6 1 44 54 (Pubitemid 38139639)
20. AP Venook KC Enders G Fleming D Hollis CG Leichman R Hohl J Byrd D Budman M Villalona J Marshall GL Rosner J Ramirez H Kastrissios MJ Ratain 2003 A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 Ann Oncol 14 12 1783 1790 (Pubitemid 38029051)
21. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea Clin Pharmacol Ther 72 3 265 275
22. S Poujol F Bressolle J Duffour AG Abderrahim C Astre M Ychou F Pinguet 2006 Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen Cancer Chemother Pharmacol 58 3 292 305 (Pubitemid 43800732)
23. MK Ma WC Zamboni KM Radomski WL Furman VM Santana PJ Houghton SK Hanna AK Smith CF Stewart 2000 Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan Clin Cancer Res 6 3 813 819 (Pubitemid 30159334)
24. Y Kawato M Aonuma Y Hirota H Kuga K Sato 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res 51 16 4187 4191
25. RP Hertzberg MJ Caranfa KG Holden DR Jakas G Gallagher MR Mattern SM Mong JO Bartus RK Johnson WD Kingsbury 1989 Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J Med Chem 32 3 715 720 (Pubitemid 19075732)
26. J Fassberg VJ Stella 1992 A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J Pharm Sci 81 7 676 684 (Pubitemid 23006796)
27. DM Ouellet GM Pollack 1995 Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats Drug Metab Dispos 23 4 478 484
28. TM Davis F Daly JP Walsh KF Ilett JP Beilby LJ Dusci PH Barrett 2000 Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes Br J Clin Pharmacol 49 3 223 230 (Pubitemid 30150983)
29. F Ezzet G Krishna DB Wexler P Statkevich T Kosoglou VK Batra 2001 A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe Clin Ther 23 6 871 885 (Pubitemid 32554569)
30. YJ Moon K Sagawa K Frederick S Zhang ME Morris 2006 Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats AAPS J 8 3 E433 E442 (Pubitemid 44096604)